Business Context and Reporting Period
This Form 8-K is filed by Integrity Applications, Inc. (not Glucotrack, Inc., which is the name of the company's product) for the reporting period ending December 19, 2012. The report details a significant regulatory milestone regarding the company's non-invasive glucose monitoring device, the GlucoTrack DF-F model.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report on a specific event and does not contain financial statements.
Material Changes and Events
- Regulatory Submission: On December 16, 2012, the Company submitted its CE Mark Technical File to DEKRA Certification B.V., the European notified body.
- Product Focus: The submission concerns the GlucoTrack DF-F non-invasive glucose monitoring device.
- Next Steps: The Company must submit additional information, including clinical evaluation data, to the Notified Body.
Outlook, Risks, and Management Commentary
Timeline and Expectations: If the Company successfully submits clinical data, the Technical File is accepted, and facility audits are satisfactory, the Company expects to receive CE Mark approval and an ISO 13485:2003 quality system certificate as early as the end of the first quarter of 2013.
Market Impact: Receipt of the CE Mark would allow the Company to market and sell the device in EU member countries and nations with Mutual Recognition Agreements (MRA) with the EU, bypassing additional national regulations regarding performance and safety.
Risks and Contingencies: There is no assurance of approval. Risks include:
- Failure to submit required clinical evaluation data or other information in a timely manner.
- Rejection of the Technical File by the Notified Body.
- Negative results from audits of facilities, quality systems, or manufacturing processes.
- General risk factors outlined in the Company's Annual Report for 2011 and Quarterly Reports for 2012.
Investor Verification Checklist
- Verify the status of the clinical evaluation data submission to DEKRA Certification B.V.
- Confirm the timeline for the completion of facility and quality system audits.
- Review the "Risk Factors" section in the Company's 2011 Annual Report and 2012 Quarterly Reports for detailed regulatory risks.
- Monitor for any updates regarding the acceptance of the Technical File by the Notified Body.